زوایفل، پیتر، بریر، فریدریک، و کیفمان، ماتیاس(1400). اقتصاد سلامت. ترجمه: سارا امامقلی پورسفیددشتی، لطفعلی عاقلی، تهران، انتشارات نور علم(نشر اصلی اثر، 2009)
سلطان زاده، جواد، الیاسی، مهدی، بامداد صوفی، جهانیار و کزازی، ابوالفضل(1396). اثر سیاستهای تنظیمی بر توانمندی نوآوری بنگاههای تولید داروی ایران. فصلنامه مدیریت نوآوری، 6(2)، 64-31. https://www.nowavari.ir/article_60172.html
سازمان غذا و داروی ایران(1396). سالنامه دارویی کشور. انتشارات سازمان غذا و دارو
عبادی، جعفر و نیکونسبتی، علی(1391). منابع طبیعی، نهادها، رشد اقتصادی، فصلنامه برنامه ریزی و بودجه،۱۷(4). https://jpbud.ir/article-1-752-fa.html
فولند، شرمن، گودمن، آلن و استانو، میرون(1397). اقتصاد سلامت و مراقبتهای سلامت، ترجمه سارا امامقلیپور سفید دشتی, علی اکبری ساری، تهران: انتشارات آثار سبحان
کارگرشهامت، بهمن؛ نویسنده: تقوا، محمدرضا و طباطبائیان، سید حبیب اله(1396). کارکردهای شبکه نوآوری تحلیلی از یادگیری فناورانه در بخش دارویی ایران. مدیریت توسعه فناوری، 5(2)، 39- 9. https://jtdm.irost.ir/article_660.html
کزازی، ابوالفضل،قاضی نوری، سید سروش،رفیع زاده تفتی، محمود و دیناروند، رسول(1399).تصمیمات استراتژیک تولید در صنعت تولید داروهای شیمیانی ایران. مجله بهبود مدیریت، 14(4)، 33- 1.
https://doi.org/10.22034/jmi.2021.118536
لی، کئون، (1399) هنر جهش اقتصادی، ترجمه حمید پاداش و روح اله کهن هوش نژاد، تهران: نشر نهادگرا(نشر اصلی اثر، 2019)
مرکز پژوهشهای مجلس شورایاسلامی(1400). ارزیابی وضعیت صنعت تولید مواد اولیه دارویی در ایران از منظر میزان تأمین بازار، ارزبری، عمق تولید، سطح فناوری و قیمت محصولات. انتشارات مرکز پژوهشهای مجلس
مرکز پژوهشهای مجلس، (1402)، سهم نهادهای شبه دولتی در اقتصاد: صنعت دارو. انتشارات مرکز پژوهشهای مجلس
Acemoglu, Daron& Robinsonm James A, (2019). The Narrow Corridor: States, Societies, and the Fate of Liberty. New York:Penguin Press
Acemoglu, Daron& Robinsonm James A, (2012). Why Nations Fail: The Origings of Power, Prosperty and Poverty, Profile Book
Acemoglu, Daron., Johnson, Simon., &Robinson, James.A. (2005). Institutions as the Fundamental Cause of Long-Run Growth, in Handbook of Economic Growth, edited by, Philippe Aghionand Steven Durlauf. Elsevier
Amsden, Alice H& Singh, A.(1994),The optimal degree of competition and dynamic efficiency in -Japan and Korea. European Economic Review,38)3),940–951. https://doi.org/10.1177/01600176251313752
Ariely, Dan.(2010).Predictably Irrational: The Hidden Forces That Shape Our Decisions. Harper Perennial
Ashiwaju,Bankole Ibrahim,Orikpete, Ochuko Felix,Alade, Elesho Yusuf, Raji, Ahmed, Adesanya, Abel Olusegun,Nwankwo& Tochukwu Chinwuba.(2023), Impact of drug price regulation on patient access to medicines: A systematic review. Matrix Science Pharma 7(4), 112-118. DOI: 10.4103/mtsp.mtsp_23_23
-Barr, Michael S, Mullainathan, Sendhil& Shafir, Eldar.(2012), Behaviorally Informed Regulation. in E. Shafir (ed), The Behavioral Foundations of Public Policy, Princeton: Princeton University Press, Chapter 26
Calfee JE, (2000), Prices, Markets and the Pharmaceutical Revolution. AEI:Washington DC;
Chang, H,&Andreoni,A.(2020).Industrial Policy in the 21st Century. Development and Change. Development and Change,51(2), 324-351. https://doi.org/10.1111/dech.12570
Chen, Benjamin Minhao&Libgober, Brian.(2024). Do Administrative Procedures Fix Cognitive Biases?, Journal of Public Administration Research and Theory,34(1),105–121, https://doi.org/10.1093/jopart/muac054
Chater N.(2024).What is the point of behavioural public policy? A contractarian approach. Behavioural Public Policy,8(2):197-211. DOI: https://doi.org/10.1017/bpp.2022.2
Thomas R.(2016).Understanding Public Policy,Pearson
Goldstein, E.,, (2019).Cognitive Psychology:Connecting Mind, Research, and Everyday Experience. Cengage Learning, Inc
Halpern SD, Truog RD, Miller FG. (2020). Cognitive Bias and Public Health Policy During the COVID-19 Pandemic. JAMA,24(4),337-338. DOI: 10.1001/jama.2020.11623
Howlett, Michael, Cashore, Benjamin, (2020), Public policy: definitions and approaches,in; Giliberto Capano, Michael Howlett, (eds), A Modern Guide to Public Policy, Edward Elgar Publishing.
Howlett, Michael, Ramesh,M& Perl, Anthony, (2020), Studying Public Policy Principles and Processes, Oxford university Press
Kahneman, Daniel, (2011), Thinking, Fast and Slow, Farrar
Kahneman, Daniel, Olivier Sibony& Cass R. Sunstein.(2021). Noise: A Flaw in Human Judgment. New York: Little Brown Spark
Kang SY, Bai G, DiStefano MJ, Socal MP, Yehia F& Anderson GF (2020).Comparative Approaches to Drug Pricing. Annu Rev Public Health.,41(2),499-512.
DOI: 10.1146/annurev-publhealth-040119-094305
Lin, Justin Yifu, (2012), New Structural Economics: A Framework for Rethinking Development and Policy, The World Bank
McKinsey.(2021).Building a more competitive US manufacturing sector
Mendoza, Roger Lee.(2019). Incentives and disincentives to drug innovation: evidence from recent literature, Journal of Medical Economics, 22(8), 713-721. DOI: 10.1080/13696998.2019.1613240
Mondliwa, P., Goga, S. & Roberts, S. (2021).Competition, Productive Capabilities and Structural Transformation in South Africa. Eur J Dev Res,33, 253–274. https://doi.org/10.1057/s41287-020-00349-x
National Academies of Sciences, Engineering, and Medicine)2018.(Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press
North, Douglass.c.(2000).The New Institutional Economics and Third World Development,Edit by J. Harriss,J.Hunter
North.Douglass.C.(1994).Economic Performance Through Time.The American Economic Review, 84(3), 359-368. http://www.jstor.org/stable/2118057.
North. Douglass C, W allis. John Joseph, Weeb, Steven B& Weingast. Barry R, (2012) Limited Access order: An Introduction to the Conceptual Framework, in: In the Shadow of Violence: Politics, Economics, and problems of Development, Cambridge university Press
North.Douglass C, Wallis. John Joseph, Weingast. Barry R, (2009), Violence and Social Orders: A Conceptual Framework for Interpreting Recorded Human History, Cambridge University Press
Robinson, James A, (1999), When Is a State Predatory?, Center for Economic Studies, University of Munich,Working Paper No. 178
Rodwin MA., (2021),Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States,International Journal of Health Services, 51(3):379-39. doi: 10.1177/0020731421996168
Rutherford, Mlacom, (2001),Institutional Economics:Then and Now,The Journal of Economic Perspectives,15(3), 173–194. DOI: 10.1257/jep.15.3.173
Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, (2021),. Drug shortage: Causes, impact, and mitigation strategies. Front Pharmacol, 12,693-726. https://doi.org/10.3389/fphar.2021.693426
Simon, Herbert A, (1955).A Behavioral Model of Rational Choice, Quarterly Journal of Economics, 69 (1), 99–118. https://doi.org/10.2307/1884852
Smith, Adam. (1776).An Inquiry into the Nature and Causes of the Wealth of Nations. edited by: Edwin Cannan
Sunstein, C. R. (2017). Nudges That Fail. Behavioural Public Policy, 1(1), 4–25. DOI: https://doi.org/10.1017/bpp.2016.3
Thaler, R. H. (2016), Behavioral Economics: Past, Present, and Future, American Economic Review,Vol 106, No7,Pp 1577–1600. DOI: 10.1257/aer.106.7.1577
Thaler, R.H. & C.R. Sunstein .(2008). Nudge: Improving Decisions about Health, Wealth, and Happiness, Revised and Expanded Edition, New York: Penguin Books.
Tversky, Amos and Kahneman, Daniel, (1974),Judgment under Uncertainty: Heuristics and Biases.” Science, 185(4157), 1124–1131. DOI: 10.1126/science.185.4157.112
WHO(2019), WHO guideline on country pharmaceutical pricing policies.
Williamson, Oliver.(2010).Transaction Cost Economics: The Natural Progression, American Economic Review, 100(3), 673–690. DOI: 10.1257/aer.100.3.673
Williamson, Oliver.(2005).Transaction Cost Economics. in: C. Menard and M. M. Shirley (eds), Handbook of New Institutional Economics, Springer
Williamson, Oliver.(2000).The New Institutional Economics: Taking Stock, Looking Ahead.Journal of Economic literature,38(3), 595–613. DOI: 10.1257/jel.38.3.595
World Bank.(2019). Behavioral Science Around The World Profiles Of 10 Countries
